Aldeyra Therapeutics, Inc. (ALDX) is a biotechnology company focused on developing and commercializing novel therapies for rare and immune-mediated diseases using its endogenously derived aldehyde technology. Established in 2004, it’s headquartered in Lexington, Massachusetts. The company's lead product candidate, reproxalap, is an aldehyde trap designed to treat dry eye disease and allergenic conjunctivitis by covalently binding to and sequestering free aldehydes.
Aldeyra operates in the healthcare sector, and its research concentrates on eye and inflammatory diseases where it believes there are unmet medical needs. It has several clinical-stage candidates, and its developmental strategy is to take these through to regulatory submission. Under its umbrella, it's developing ADX-102, a novel drug candidate designed to modify signaling metabolic pathways in inflammation, cell death, and immunity.
The company has had immense success within clinical trials for its lead product reproxalap. Results from various trials have consistently demonstrated a rapid and statistically significant improvement in the signs and symptoms of dry eye disease and allergic conjunctivitis. Notably, reproxalap is projected to be the first drug approved for both of these indications.
Apart from reproxalap, Aldeyra Therapeutics also currently has a pipeline of other promising drug candidates. These includes ADX-629, a first-in-class orally administered RASP (Reactive Aldehyde Species) inhibitor, for the treatment of COVID-19, psoriasis, and atopic asthma; ADX-2191, a generic version of methotrexate for the treatment of proliferative vitreoretinopathy; and ADX-1612, a heat shock protein 90 (Hsp90) inhibitor being developed for the treatment of lymphoproliferative inflammatory diseases.
Under the able leadership of President and CEO Todd C. Brady, M.D., Ph.D., Aldeyra Therapeutics has grown to become a global brand in the biotechnology industry, collaborating with various institutions in clinical trials. The overall goal and mission of Aldeyra Therapeutics are to improve lives by inventing, developing, and commercializing next-generation medicines that address unmet medical needs.
Aldeyra Therapeutics is committed to transforming therapies for patients with unmet medical needs by using its propriety reproxalap and other drug candidates in their product pipeline. The company seeks to continue providing quality innovative solutions in tackling rare and immune-mediated diseases globally. Looking into the future, Aldeyra Therapeutics aims to continue to lead the biotechnology industry with its inventive solutions, thereby improving patient care conditions and experiences.